

NOTICE OF CHANGE IN CORPORATE STRUCTURE

PURSUANT TO SECTION 4.9 OF NATIONAL INSTRUMENT 51-102

1. Names of the parties to the transaction

Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the "**Corporation**")

2. Description of the transaction

On December 12, 2018, holders of common shares of the Corporation approved a special resolution to change the name of the Corporation from "Pediapharm Inc." to "Medexus Pharmaceuticals Inc." (the "**Name Change**"). Additionally, on December 12, 2018, the Corporation implemented its previously announced consolidation (the "**Consolidation**") of its common shares on the basis of one (1) new common share for each previously outstanding fifteen (15) common shares. In the event that the Consolidation would otherwise result in the issuance of a fractional Common Share, no fractional Common Share will be issued and such fraction will be rounded up to the nearest whole number if 0.5 or greater and down to the nearest whole number if less than 0.5, without any additional compensation. In addition, the exercise price and number of common shares of the Corporation issuable upon the exercise of outstanding options, warrants, convertible debentures and other convertible securities of the Corporation will be proportionately adjusted as a result of the Consolidation. The common shares of the Corporation are expected to be trading on the TSX Venture Exchange under the new corporate name, on a post-consolidated basis, and under the new stock symbol "MDP" at market opening on December 19, 2018.

For additional information related to the Name Change and Consolidation, please refer to the Information Circular of the Corporation dated November 12, 2018 which has been filed under the Corporation's profile on SEDAR at www.sedar.com

3. Effective date of the transaction

The Name Change and Consolidation were effective as of December 12, 2018.

4. Names of each party, if any, that ceased to be a reporting issuer after the transaction and of each continuing entity

Following the effective date of the Name Change, the company ceased to report under the name of "Pediapharm Inc." and will continue to be a reporting issuer under the name "Medexus Pharmaceuticals Inc."

5. Date of reporting issuer's first financial year-end subsequent to the transaction (if paragraph (a) or subparagraphs (b)(ii) of s.4.9 applies)

N/A

6. Periods, including comparative periods, if any, of the Interim and Annual Financial

Statements required to be filed for the reporting issuer's first financial year after the transaction form (if paragraph (a) or subparagraph (b)(ii) of s.4.9 applies)

N/A

- 7. Documents filed under NI 51-102 that described the transaction and where those documents can be found in electronic form (if paragraph (a) or subparagraph (b)(ii) of s.4.9 applies)**

N/A